153 related articles for article (PubMed ID: 31865178)
1. PIK3CA and KRAS Amplification in Esophageal Adenocarcinoma and their Impact on the Inflammatory Tumor Microenvironment and Prognosis.
Essakly A; Loeser H; Kraemer M; Alakus H; Chon SH; Zander T; Buettner R; Hillmer AM; Bruns CJ; Schroeder W; Gebauer F; Quaas A
Transl Oncol; 2020 Feb; 13(2):157-164. PubMed ID: 31865178
[TBL] [Abstract][Full Text] [Related]
2. GATA binding protein 6 (GATA6) is co-amplified with PIK3CA in patients with esophageal adenocarcinoma and is linked to neoadjuvant therapy.
Plum PS; Löser H; Zander T; Essakly A; Bruns CJ; Hillmer AM; Alakus H; Schröder W; Büttner R; Gebauer F; Quaas A
J Cancer Res Clin Oncol; 2021 Apr; 147(4):1031-1040. PubMed ID: 33300112
[TBL] [Abstract][Full Text] [Related]
3. The expression of the immune checkpoint regulator VISTA correlates with improved overall survival in pT1/2 tumor stages in esophageal adenocarcinoma.
Loeser H; Kraemer M; Gebauer F; Bruns C; Schröder W; Zander T; Persa OD; Alakus H; Hoelscher A; Buettner R; Lohneis P; Quaas A
Oncoimmunology; 2019; 8(5):e1581546. PubMed ID: 31069143
[TBL] [Abstract][Full Text] [Related]
4. Integrin alpha V (ITGAV) expression in esophageal adenocarcinoma is associated with shortened overall-survival.
Loeser H; Scholz M; Fuchs H; Essakly A; Damanakis AI; Zander T; Büttner R; Schröder W; Bruns C; Quaas A; Gebauer F
Sci Rep; 2020 Oct; 10(1):18411. PubMed ID: 33110104
[TBL] [Abstract][Full Text] [Related]
5. Dickkopf-2 (DKK2) as Context Dependent Factor in Patients with Esophageal Adenocarcinoma.
Schiffmann LM; Loeser H; Jacob AS; Maus M; Fuchs H; Zhao Y; Tharun L; Essakly A; Iannos Damanakis A; Zander T; Büttner R; Schröder W; Bruns C; Quaas A; Gebauer F
Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32075129
[TBL] [Abstract][Full Text] [Related]
6. BRAF, PIK3CA, and HER2 Oncogenic Alterations According to KRAS Mutation Status in Advanced Colorectal Cancers with Distant Metastasis.
Nam SK; Yun S; Koh J; Kwak Y; Seo AN; Park KU; Kim DW; Kang SB; Kim WH; Lee HS
PLoS One; 2016; 11(3):e0151865. PubMed ID: 26991109
[TBL] [Abstract][Full Text] [Related]
7. HER2/neu (ERBB2) expression and gene amplification correlates with better survival in esophageal adenocarcinoma.
Plum PS; Gebauer F; Krämer M; Alakus H; Berlth F; Chon SH; Schiffmann L; Zander T; Büttner R; Hölscher AH; Bruns CJ; Quaas A; Loeser H
BMC Cancer; 2019 Jan; 19(1):38. PubMed ID: 30621632
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive Genomic Profiling of Advanced Esophageal Squamous Cell Carcinomas and Esophageal Adenocarcinomas Reveals Similarities and Differences.
Wang K; Johnson A; Ali SM; Klempner SJ; Bekaii-Saab T; Vacirca JL; Khaira D; Yelensky R; Chmielecki J; Elvin JA; Lipson D; Miller VA; Stephens PJ; Ross JS
Oncologist; 2015 Oct; 20(10):1132-9. PubMed ID: 26336083
[TBL] [Abstract][Full Text] [Related]
9. Immune profile and immunosurveillance in treatment-naive and neoadjuvantly treated esophageal adenocarcinoma.
Wagener-Ryczek S; Schoemmel M; Kraemer M; Bruns C; Schroeder W; Zander T; Gebauer F; Alakus H; Merkelbach-Bruse S; Buettner R; Loeser H; Thelen M; Schlößer HA; Quaas A
Cancer Immunol Immunother; 2020 Apr; 69(4):523-533. PubMed ID: 31960110
[TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor receptor, phosphatidylinositol-3-kinase catalytic subunit/PTEN, and KRAS/NRAS/BRAF in primary resected esophageal adenocarcinomas: loss of PTEN is associated with worse clinical outcome.
Bettstetter M; Berezowska S; Keller G; Walch A; Feuchtinger A; Slotta-Huspenina J; Feith M; Drecoll E; Höfler H; Langer R
Hum Pathol; 2013 May; 44(5):829-36. PubMed ID: 23158210
[TBL] [Abstract][Full Text] [Related]
11. Expression of Immune Checkpoint Regulators IDO, VISTA, LAG3, and TIM3 in Resected Pancreatic Ductal Adenocarcinoma.
Popp FC; Capino I; Bartels J; Damanakis A; Li J; Datta RR; Löser H; Zhao Y; Quaas A; Lohneis P; Bruns CJ; On Behalf Of The Pancalyze Study Group
Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34072549
[TBL] [Abstract][Full Text] [Related]
12. Loss of the SWI/SNF-ATPase subunit members SMARCF1 (ARID1A), SMARCA2 (BRM), SMARCA4 (BRG1) and SMARCB1 (INI1) in oesophageal adenocarcinoma.
Schallenberg S; Bork J; Essakly A; Alakus H; Buettner R; Hillmer AM; Bruns C; Schroeder W; Zander T; Loeser H; Gebauer F; Quaas A
BMC Cancer; 2020 Jan; 20(1):12. PubMed ID: 31906887
[TBL] [Abstract][Full Text] [Related]
13. PIK3CA amplification is associated with poor prognosis among patients with curatively resected esophageal squamous cell carcinoma.
Kim HS; Lee SE; Bae YS; Kim DJ; Lee CG; Hur J; Chung H; Park JC; Shin SK; Lee SK; Lee YC; Kim HR; Shim YM; Jewell SS; Kim H; Choi YL; Cho BC
Oncotarget; 2016 May; 7(21):30691-701. PubMed ID: 27095573
[TBL] [Abstract][Full Text] [Related]
14. HER2 status in lung adenocarcinoma: a comparison of immunohistochemistry, fluorescence in situ hybridization (FISH), dual-ISH, and gene mutations.
Yoshizawa A; Sumiyoshi S; Sonobe M; Kobayashi M; Uehara T; Fujimoto M; Tsuruyama T; Date H; Haga H
Lung Cancer; 2014 Sep; 85(3):373-8. PubMed ID: 25047676
[TBL] [Abstract][Full Text] [Related]
15.
Holst F; Werner HMJ; Mjøs S; Hoivik EA; Kusonmano K; Wik E; Berg A; Birkeland E; Gibson WJ; Halle MK; Trovik J; Cherniack AD; Kalland KH; Mills GB; Singer CF; Krakstad C; Beroukhim R; Salvesen HB
Clin Cancer Res; 2019 Jan; 25(1):334-345. PubMed ID: 30442683
[TBL] [Abstract][Full Text] [Related]
16. Elevated X-linked inhibitor of apoptosis protein (XIAP) expression uncovers detrimental prognosis in subgroups of neoadjuvant treated and T-cell rich esophageal adenocarcinoma.
Schiffmann LM; Göbel H; Löser H; Schorn F; Werthenbach JP; Fuchs HF; Plum PS; Bludau M; Zander T; Schröder W; Bruns CJ; Kashkar H; Quaas A; Gebauer F
BMC Cancer; 2019 May; 19(1):531. PubMed ID: 31151416
[TBL] [Abstract][Full Text] [Related]
17. Coexistent mutations of KRAS and PIK3CA affect the efficacy of NVP-BEZ235, a dual PI3K/MTOR inhibitor, in regulating the PI3K/MTOR pathway in colorectal cancer.
Kim A; Lee JE; Lee SS; Kim C; Lee SJ; Jang WS; Park S
Int J Cancer; 2013 Aug; 133(4):984-96. PubMed ID: 23475782
[TBL] [Abstract][Full Text] [Related]
18. HER2 Confers Resistance to Foretinib Inhibition of MET-Amplified Esophageal Adenocarcinoma Cells.
Goltsov AA; Fang B; Pandita TK; Maru DM; Swisher SG; Hofstetter WL
Ann Thorac Surg; 2018 Feb; 105(2):363-370. PubMed ID: 29223420
[TBL] [Abstract][Full Text] [Related]
19. Relationships among
Wan XB; Wang AQ; Cao J; Dong ZC; Li N; Yang S; Sun MM; Li Z; Luo SX
World J Gastroenterol; 2019 Feb; 25(7):808-823. PubMed ID: 30809081
[TBL] [Abstract][Full Text] [Related]
20. Prognostic relevance of gene amplifications and coamplifications in breast cancer.
Al-Kuraya K; Schraml P; Torhorst J; Tapia C; Zaharieva B; Novotny H; Spichtin H; Maurer R; Mirlacher M; Köchli O; Zuber M; Dieterich H; Mross F; Wilber K; Simon R; Sauter G
Cancer Res; 2004 Dec; 64(23):8534-40. PubMed ID: 15574759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
